Synapse - Michael Morris

Results (588)

[(177)Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial

Meeting Abstract

Vaishampayan, N.; Morris, M. J.; Krause, B. J.; Vogelzang, N. J.; Kendi, A. T.; Nordquist, L. T.; Calais, J.; Nagarajah, J.; Beer, T. M.; El-Haddad, G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Incorporation of intrapatient response heterogeneity using (18)F-NaF PET/CT imaging improves outcome prediction models for metastatic prostate cancer patients

Meeting Abstract

Perk, T. G.; Yip, S. S. F.; Weisman, A. J.; Houshmandi, S. S.; Heath, E. I.; Morris, M. J.; Madan, R. A.; McNeel, D. G.; Apolo, A. B.; Kyriakopoulos, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer

Meeting Abstract

Morris, M. J.; Sartor, A. O.; Wong, J. Y. C.; Max, S. I.; Xie, H.; Yu, A.; Divgi, C. R.; Patricia, D.; Avadhani, A. N.; Pandit-Taskar, N.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P)

Meeting Abstract

McConkey, D. J.; Choi, W.; Halabi, S.; Luo, B.; Al-Ahmadie, H. A.; Rosenberg, J. E.; Mountain, J.; Regazzi, A. M.; Fong, M.; Iyer, G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscleinvasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)

Meeting Abstract

Iyer, G.; Ballman, K. V.; Atherton, P. J.; Murray, K.; Kwok, Y.; Steen, P. D.; Baghaie, S.; Rosenberg, J. E.; Morris, M. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance)

Meeting Abstract

Iyer, G.; Halabi, S.; Luo, B.; Rosenberg, J. E.; Choi, W.; Al-Ahmadie, H. A.; Mountain, J.; Regazzi, A. M.; Fong, M.; Mouw, K. W.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)

Meeting Abstract

Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Chen, R. C.; Chan, T. A.; Dercle, L.; Wen, Y.; Sridhar, S. S.; Yen, A. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Meeting Abstract

Halabi, S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Parmar, M. K. B.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score

Meeting Abstract

Gorin, M. A.; Rowe, S. P.; Pienta, K. J.; Carroll, P. R.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M.; Alva, A. S.; Patnaik, A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save